Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
1.040
-0.030 (-2.80%)
At close: Oct 14, 2026, 4:00 PM EDT
1.030
-0.010 (-0.96%)
After-hours: Oct 14, 2026, 7:36 PM EDT
Imunon Employees
Imunon had 20 employees as of December 31, 2025. The number of employees decreased by 5 or -20.00% compared to the previous year. That makes Imunon the 38,315th largest employer in the world and 5,534th in the United States.
Employees
20
Change (1Y)
-5
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$736,658
Market Cap
5.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 20 | -5 | -20.00% |
| Dec 31, 2024 | 25 | -8 | -24.24% |
| Dec 31, 2023 | 33 | 2 | 6.45% |
| Dec 31, 2022 | 31 | 2 | 6.90% |
| Dec 31, 2021 | 29 | 2 | 7.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| AIM ImmunoTech | 21 |
| NeuroSense Therapeutics | 17 |
| Processa Pharmaceuticals | 12 |
| Traws Pharma | 7 |
| Alzamend Neuro | 6 |
| Enveric Biosciences | 6 |
| KALA BIO | 6 |
IMNN News
- 6 days ago - IMUNON to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - IMUNON Converts $1.2 Million of Debt-to-Equity - GlobeNewsWire
- 20 days ago - Imunon presents update on its IMNN-001 development program - TheFly
- 20 days ago - IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan - GlobeNewsWire
- 21 days ago - Imunon Transcript: R&D Day 2026 - Transcripts
- 21 days ago - Imunon Slides: FY 2026 - Filings
- 22 days ago - Imunon announces IDMC recommends continued Phase 2 development of IMNN-001 - TheFly
- 22 days ago - IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review - GlobeNewsWire